|

JSKN016 Clinical Trials

2 actively recruiting trials

No change since May 2026

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd2

Indications

  • Cancer2
  • Metastatic HER2-Negative Breast Cancer1
  • Inoperable Locally Advanced HER2-Negative Breast Cancer1
  • Advanced Non-Small Cell Lung Cancer1
  • Lung Cancer1

Other2 trials

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Phase 1
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.